| Biomarker ID | 1770 |
| PMID | 30334974 |
| Year | 2018 |
| Biomarker | PCA3 |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Blood |
| Subjects | Humans |
| Regulation | Upregulated in Stage T3-T4 |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Prostate Cancer Vs Benign prostatic hyperplasia |
| Type of Biomarker | Diagnostic |
| Cohort | 100 patients were analysed for the study. 43 patients had PCa and 57 had benign prostatic hyperplasia group (BPH) |
| Senstivity | NA |
| Specificity | Full Dataset: 82.5%; PSA range 4 to 10ng/mL: 100% |
| AUC | Full Dataset: 0.667 (95% CI: 0.558-0.775); PSA range 4 to 10ng/mL: 0.843 (95% CI: 0.687–-0.998) |
| Accuracy | NA |
| Level Of Significance | NA |
| Method Used | qRT-PCR |
| Clinical | No |
| Remarks | PCA3 cutoff: 121.2; PSA range 4 to 10ng/mL: 349.2 |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |